Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2011-03-29
2011-03-29
Salimi, Ali R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S204100, C435S005000
Reexamination Certificate
active
07914797
ABSTRACT:
The present invention relates to influenza vaccines for human and veterinary use. In particular, the present invention provides a vaccine able to effect long term and cross-strain protection by including at least two influenza virus epitopes expressed as a chimeric polypeptide wherein at least one epitope is influenza A virus matrix protein epitope and the second epitope is a haemagglutinin peptide epitope.
REFERENCES:
patent: 4474757 (1984-10-01), Arnon et al.
patent: 6130082 (2000-10-01), Majarian
patent: 2004/0223976 (2004-11-01), Bianchi et al.
patent: WO 93/20846 (1993-10-01), None
patent: WO 94/26903 (1994-11-01), None
patent: WO 98/23735 (1998-06-01), None
patent: WO 99/07839 (1999-02-01), None
patent: WO 00/32228 (2000-06-01), None
patent: WO 0200885 (2002-03-01), None
patent: WO 2004/080403 (2004-09-01), None
Horimoto et al, Microbes and Infection, Apr. 9, 2004, vol. 6, pp. 579-583.
Ada, G. L. and Jones, P.D. (1986) The immune response to influenza infection. Current Topics Microbiology and Immunology 128:1-54.
Arnon, R. et al., (2001) Peptide-based synthetic recombinant vaccines with anti-viral efficacy. Biologicals 29(3-4):237-242.
Ben-Yedidia, Tamar et al., (1999) Intranasal administration of peptide vaccine protects human/mouse radiation chimera from influenza infection. Int Immunol. 11(7):1043-51.
Gianfrani, Carmen et al., (2000) Human memory CTL response specific for influenza A virus is broad and multispecific. Hum Immunol. 61(5):438-452.
Ibrahim, George F. et al., (1985) Method for the isolation of highly purifiedSalmonella flagellins. J Clin Microbiol. 22(6):1040-4.
Lamb, Robert A. et al., (1985) Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 40:627-633.
Levi, Raphael and Arnon, Ruth (1996) Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection. Vaccine 14(1):85-92.
Liu, Wanli et al., (2005) Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design. Microbes Infect. 7(2):1717-177.
Shapira, Michal et al., (1985) A synthetic vaccine against influenza with built-in adjuvanticity. Int J Immunopharmacol. 7(5):719-723.
Slepushkin, Vladimir A. et al., (1995) Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 13(15):1399-1402.
Townsend, A. R. M. and Skehel, J. J. (1984) The influenza A virus nucleoprotein gene controls the induction of both subtype specific and cross-reactive cytotoxic T cells. J Exp Med. 160(2):552-563.
Zou, Peng et al., (2005) The epitope recognized by a monoclonal antibody in influenza A virus M2 protein is immunogenic and confers immune protection. Int Immunopharmacol. 5(4):631-635.
Ben-Yedidya, Tamar et al., XP-000914823, “Efficacy Of Anti-Influenza Peptide Vaccine In Aged Mice”,. Mechanisms of Ageing and Development, vol. 104(1), pp. 11-23 (1998).
International Search Report PCT/IL2006/001403, 2006.
Ze Chen et al., “Enhanced Protection Against a Lethal Influenza Virus Challenge by Immunization With Both Hemagglutinin- and Neuraminidase-Expressing DNAs”, Vaccine, vol. 17, pp. 653-659 (1999).
Sung Ho Jeon et al., “Intranasal Immunization With Synthetic Recombinant Vaccine Containing Multiple Epitopes Of Influenza Virus,” Vaccine, vol. 20, pp. 2772-2780 (2002).
Tamar Ben-Yedidia et al.,“Review: Towards an Epitope-Based Human Vaccine For Influenza”, Human Vaccines vol. 1, No. 3, pp. 95-101 (2005).
Arnon Ruth
Ben-Yedidia Tamar
Salimi Ali R.
Winston & Strawn LLP
Yeda Research and Development Co. Ltd. at the Weizmann Institute
LandOfFree
Influenza vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Influenza vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Influenza vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2760199